CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
CytoSorbents Corporation, a leader in critical care immunotherapy specializing in blood purification, received an additional $5 million from the Life Sciences Group of Bridge Bank.
CytoSorbents Corporation (“CytoSorbents” or the “Company”) and its U.S. operating subsidiary, CytoSorbents Medical, Inc. began working with Bridge Bank in June, 2016 when they secured an initial $5 million term loan. On June 30, 2017 the Company expanded its relationship to secure an additional $5 million of funding available under their agreement, totaling it’s borrowings to $10 million. The Company intends to use the loan to provide working capital to fund ongoing operations and support clinical trials.
"With our existing cash on hand, this non-dilutive financing further strengthens our balance sheet at an attractive cost of capital and provides sufficient working capital for the foreseeable future, allowing us to continue to pursue our aggressive growth strategy and clinical trial objectives as we increase product sales worldwide and move closer to operating cash flow breakeven,” stated Kathleen Bloch, CPA, MBA, chief financial officer of CytoSorbents Corporation. “We welcome this continuation and expansion of our important relationship with Bridge Bank, a reputable and premier industry provider with a broad scope of financial services.”
“We’ve been working with CytoSorbents for over a year now and believe they possess a truly innovative technology in the life sciences space which could transform critical care medicine and cardiac surgery and save lives throughout the world,” said Justin McDonie, senior vice president for Bridge Bank. “We are pleased to provide this additional capital to support CytoSorbents’ growth at this important juncture in their evolution.”
ABOUT BRIDGE BANK
Bridge Bank is a division of Western Alliance Bank, Member FDIC, the go-to bank for business in its growing markets. Bridge Bank was founded in 2001 in Silicon Valley to offer a better way to bank for small-market and middle-market businesses across many industries, as well as emerging technology companies and the private equity community. Geared to serving both venture-backed and non-venture-backed companies, Bridge Bank offers a broad scope of financial solutions including growth capital, equipment and working capital credit facilities, sustainable energy project finance, venture debt, treasury management, asset-based lending, SBA and commercial real estate loans, ESOP finance and a full line of international products and services. Based in San Jose, Bridge Bank has eight offices in major markets across the country along with Western Alliance Bank’s robust national platform of specialized financial services. Western Alliance Bank is the primary subsidiary of Phoenix-based Western Alliance Bancorporation. One of the country’s top-performing banking companies, Western Alliance ranks #4 on the Forbes 2017 “Best Banks in America” list.
ABOUT CYTOSORBENTS CORPORATION (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb® has been used safely in more than 23,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Recent NewsBridge Bank Finalizes $8 Million New Credit Facility with ANEXIOBridge Bank extends credit facility to Tabula Rasa HealthcareBridge Bank extends credit facility to InstaMedBridge Bank provides $4 million debt facility to leading RegTech provider PerformLineBridge Bank Hosts 7th Annual Economic Summit
Recent InsightsThe Biggest Trends in Hotel Franchising - 2017 EditionMobile Banking Helps Businesses On The GoConsider the Business Benefits of Payroll Cards — and Keep Employees HappyThe Treasury Manager Today: A Strategic Role for Changing TimesMilestone Offshore Wind Project Approved in Europe
Our client, @EksoBionics , has partnered with @Ford to help factory workers become more productive while avoiding f… twitter.com/i/web/status/9… - 2 weeks 2 days agoIn addition to figuring out how to extend your stay in Florida, we hope your #FVCC2018 agenda included meeting our team!What's next for the U.S. dollar? westernalliancebancorporation.com/bridge-bank-ho… - 3 weeks 3 days agoAs a sustaining sponsor we are at #FVCC2018 and look forward to making meaningful connections with you. We can’t wait!Bridge Bank’s technology group will be attending the Florida Venture Capital Conference January 29 – 31 #FVCC2018Government shutdown ends, central banks are now in focus. westernalliancebancorporation.com/bridge-bank-ho… - about 1 month 1 day agoRob Lake, head of Bridge Bank’s Life Sciences group, has a prediction for #JPM18. pic.twitter.com/R8keloGcVmThe Bridge Bank Life Sciences group will be attending #JPM18 in San Francisco, Jan. 8 - 11. Let us know if you'd like to connect.ow.ly/GqxL30heGRQ - about 2 months 1 week ago Markets look to the Fed, ECB, and BoE for signals ahead of the next year.Tax reform hurdles weigh down the dollar, as growth lifts euro. ow.ly/wm7w30gJGCf - about 3 months 3 days agoIt was wonderful meeting so many great friends at #PACTcapcon. Looking forward to connecting again soon!Day 2 at #PACTcapcon. If we didn’t get a chance to meet and chat yesterday, stop by and say hello!It was wonderful meeting some great new friends at #PACTcapcon today. Looking forward to meeting more of you tomorrow!Central bank decisions and a heavy docket look to shape this week's FX action. ow.ly/GUb030geH4R - about 3 months 3 weeks agoIf you’re attending #PACTcapcon 11/1 & 11/2, we want to meet you! Come say hello to Al Spurgin, Roger Klarmann, Kat… twitter.com/i/web/status/9… - about 3 months 3 weeks agoCan your business defend itself against cyber crime? #cybersecurity ow.ly/itLZ30gg7kp - about 3 months 3 weeks agoThis week's FX Commentary is here! westernalliancebancorporation.com/bridge-bank-ho… - about 4 months 1 day agoWe’re excited to have the head of our International Banking team, Ken Rosenberg, present at the International Consu… twitter.com/i/web/status/9… - about 4 months 7 days agoBridge Bank's International Banking Group has launched weekly FX Commentary on the global markets. Start your week… twitter.com/i/web/status/9… - about 4 months 1 week agoDon't miss the #Fintech boat, US administration to focus on industry comptitiveness according to @Nasdaq: bit.ly/2mVvnyZ - about 11 months 1 week ago@Fortune discusses how the VC funding gender gap is actually getting worse: for.tn/2nzP4sW - about 11 months 1 week agoWhat will determine the future of #fintech? According to @TheNextWeb, it’s #AI. Read more: bit.ly/2moerie - about 11 months 2 weeks agoAccording to @TheEconomist, private equity deals are heating up. Find out why here:econ.st/2m1sSZw - about 11 months 3 weeks agoJoin leading dealmakers for a live webcast on financing emerging growth companies w/ debt ft. Mike Lederman on 3/16 bit.ly/2m3JFKl - about 11 months 3 weeks agoBe sure to check out @Entrepreneur’s list of the top 12 #fintech companies to watch: bit.ly/2lQ4jA0 - about 11 months 3 weeks agoAn Indiana Senate panel has approved the advancement of a bill intended to reduce solar power incentives.bit.ly/2le7QFP - about 11 months 3 weeks agoWhat are the advantages of Regulation A+ venture capital? @Forbes has the answers here: bit.ly/2mctMoK - about 12 months agoAccording to @Nasdaq, renewable resrouces are among the top global trend creating invesment value this year: bit.ly/2kCVhCI - about 1 year agoCleantech venture capital is on the rise thanks to newfound market confidence. So what does its future look like? bit.ly/2lXvCFQ - about 1 year 1 day agoCEO Dan Myers discusses Bridge Bank growth and our approach to the current market, read more from TechFlash Editor,… twitter.com/i/web/status/8… - about 1 year 2 days agoCheck out the #cleantech startups that VCs have their eye on for 2017: bit.ly/2jYooot - about 1 year 1 week agoWhat does the future of clean energy look like under the Trump administration? @mercnews has the answers: bayareane.ws/2kAyNWF - about 1 year 1 week agoThe startup industry is headed internationally as more startups apply for funding. Read more on @Forbes bit.ly/2kALikZ - about 1 year 1 week agoAccording to @Bloomberg, #LifeSciences isn’t just thriving, it’s paving the way for new innovation. Read more: bit.ly/2kpAZOy - about 1 year 2 weeks agoClient @BuyerQuest demonstrates continued growth and innovation as they secure $4 million in financing bit.ly/2kazipW - about 1 year 2 weeks agoThe biotech era is not over yet. @TheStreet tells us how the sector will rebound with 3 key factors. bit.ly/2jfHhhK - about 1 year 3 weeks agoSilicon Valley, want to know what to expect under Trump’s administration? @Recode has the answers and more. bit.ly/2j5Oi9q - about 1 year 3 weeks ago@AppDynamics prepares to be the first #IPO of 2017...but it comes with a catch. @CNBC explains: cnb.cx/2iTzaHc - about 1 year 4 weeks ago